Novavax, Inc. (LON:0A3S)

Market Cap	752.34M
Revenue (ttm)	971.33M
Net Income (ttm)	370.51M
Shares Out	n/a
EPS (ttm)	2.30
PE Ratio	2.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,638
Average Volume	98,302
Open	6.44
Previous Close	6.48
Day's Range	6.41 - 6.58
52-Week Range	5.02 - 17.81
Beta	2.77
RSI	43.86
Earnings Date	Aug 8, 2025

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 952
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3S

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD